A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese (OGSG1001).
Koichi Taira
No relevant relationships to disclose
Motoki Yoshida
No relevant relationships to disclose
Naotoshi Sugimoto
No relevant relationships to disclose
Takayuki Kii
No relevant relationships to disclose
Shin Kuwakado
No relevant relationships to disclose
Mutsumi Fukunaga
No relevant relationships to disclose
Hiroko Hasegawa
No relevant relationships to disclose
Takeshi Kato
No relevant relationships to disclose
Yasuhiro Miyake
No relevant relationships to disclose
Taishi Hata
No relevant relationships to disclose
Yukihiko Tokunaga
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Haruko Daga
No relevant relationships to disclose
Tetsuhiro Yoshinami
No relevant relationships to disclose
Toshio Shimokawa
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Yukinori Kurokawa
No relevant relationships to disclose
Taroh Satoh
No relevant relationships to disclose
Toshimasa Tsujinaka
No relevant relationships to disclose
Hiroshi Furukawa
No relevant relationships to disclose